Corcept Therapeutics Accused of Misleading Investors in Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CORT?
Source: PRnewswire
- Lawsuit Background: Robbins LLP has alerted investors about a class action filed on behalf of shareholders who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, alleging the company misled investors regarding its new drug application process.
- Product Candidate: Corcept's lead product candidate, relacorilant, is being developed to treat hypercortisolism (Cushing's syndrome), but the company's claims of “powerful support” from clinical trials starkly contrast with the FDA's actual feedback regarding the NDA.
- FDA Response: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the NDA of relacorilant, requiring additional evidence of effectiveness, which caused the stock price to plummet from $70.20 to $34.80, a decline of 50.4%.
- Investor Impact: This stock price drop not only highlights the risks associated with the FDA's review of relacorilant but also exposes investors to significant losses, prompting Robbins LLP to seek representation for shareholders in pursuit of compensation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 34.080
Low
50.00
Averages
91.00
High
121.00
Current: 34.080
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lawsuit Claims Management Concealed FDA Warnings
- Lawsuit Background: Hagens Berman reminds investors in Corcept Therapeutics that they must apply to be Lead Plaintiff in the securities class action by April 21, 2026, to recover losses incurred during the class period from October 31, 2024, to December 30, 2025.
- Concealment of FDA Warnings: The lawsuit alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical FDA warnings communicated privately, which misled investors about the company's prospects.
- Investor Losses: The action seeks to recover losses for all individuals and entities who purchased Corcept common stock during the class period, highlighting significant deficiencies in the company's transparency that could have long-term negative impacts on its stock price.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, providing a potential avenue for investors to address corporate misconduct while revealing more internal issues within the company.
See More
Multiple Companies Facing Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 25, 2025, to February 2, 2026, PayPal is accused of overstating its business execution capabilities, misleading investors about its prospects, with a class action deadline of April 20, 2026.
- NuScale Power Risks: NuScale Power faces allegations of failing to disclose significant risks associated with its nuclear projects during the period from May 13, 2025, to November 6, 2025, with a class action deadline also set for April 20, 2026.
- Corcept Therapeutics Allegations: From October 31, 2024, to December 30, 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, with a class action deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is alleged to have failed to disclose a 39% increase in sales and marketing expenses during its IPO period in 2025, with a class action deadline of April 24, 2026.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Corcept Therapeutics, aiming to recover damages for investors who purchased securities between October 31, 2024, and December 30, 2025, reflecting strong investor concerns over potential fraudulent activities by the company.
- False Statements Allegations: The complaint alleges that executives made materially false statements regarding the efficacy of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA had raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Undisclosed Regulatory Risks: The lawsuit highlights that Corcept failed to disclose the significant risk that its relacorilant NDA might not be approved, creating a lack of transparency that exposes investors to substantial risks and negatively impacts the company's market reputation.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC emphasizes that they will represent investors on a contingency fee basis, meaning they will only charge fees if the lawsuit is successful, demonstrating their commitment to protecting investor rights and interests.
See More
Corcept Therapeutics Board Member Buys Over $3M in Shares
- Board Member Purchase: Leonard Baker Jr., a board member of Corcept Therapeutics, purchased 100,000 shares at an average price of approximately $33.14 each, totaling over $3 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: This purchase raised Baker Jr.'s direct ownership in Corcept by about 2%, bringing his total to approximately 1.1 million shares, reflecting his recognition of the company's long-term value.
- Legal Challenge Context: The transaction occurred shortly after an unfavorable ruling in Corcept's patent dispute with Teva Pharmaceuticals, suggesting Baker Jr.'s confidence in the company's ability to navigate challenges despite legal setbacks.
- Future Revenue Guidance: Corcept outlines a revenue guidance of $900 million to $1 billion for 2026, as the anticipated approval of relacorilant in oncology approaches, sustaining market expectations for future growth.
See More
Insperity and Corcept Executives Increase Stock Holdings
- Insperity CEO Purchase: Insperity's CEO Paul J. Sarvadi bought 201,987 shares of NSP at $23.21 each on Thursday, totaling an investment of $4.69 million, indicating strong confidence in the company's future prospects.
- Positive Stock Performance: As of Friday, Insperity's stock rose approximately 10.8%, with Sarvadi's investment currently yielding about 9.4% profit, reflecting a favorable market response to the stock.
- Corcept Executive Acquisition: G. Leonard Baker Jr. purchased 100,000 shares of Corcept Therapeutics at $33.14 each on Tuesday, amounting to $3.31 million, marking his first purchase in the past year and signaling optimism about the company's outlook.
- Market Reaction: As of Friday, Corcept Therapeutics' stock increased by about 4.7%, with Baker Jr.'s investment also achieving approximately 9.4% profit, demonstrating market recognition of the stock.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to move for Lead Plaintiff in the ongoing securities class action is April 21, 2026, urging those who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: The lawsuit, Allegheny County v. Corcept, alleges that throughout the Class Period from 2024 to 2025, the company misled investors by failing to disclose FDA warnings regarding the efficacy of its lead drug candidate, relacorilant, leading to significant investor deception.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Reed Kathrein, a partner at Hagens Berman, highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, which may have led investors to misjudge the company's prospects, exacerbating their losses.
See More
Lawsuit Claims Management Concealed FDA Warnings
- Lawsuit Background: Hagens Berman reminds investors in Corcept Therapeutics that they must apply to be Lead Plaintiff in the securities class action by April 21, 2026, to recover losses incurred during the class period from October 31, 2024, to December 30, 2025.
- Concealment of FDA Warnings: The lawsuit alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical FDA warnings communicated privately, which misled investors about the company's prospects.
- Investor Losses: The action seeks to recover losses for all individuals and entities who purchased Corcept common stock during the class period, highlighting significant deficiencies in the company's transparency that could have long-term negative impacts on its stock price.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, providing a potential avenue for investors to address corporate misconduct while revealing more internal issues within the company.
See More
Multiple Companies Facing Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 25, 2025, to February 2, 2026, PayPal is accused of overstating its business execution capabilities, misleading investors about its prospects, with a class action deadline of April 20, 2026.
- NuScale Power Risks: NuScale Power faces allegations of failing to disclose significant risks associated with its nuclear projects during the period from May 13, 2025, to November 6, 2025, with a class action deadline also set for April 20, 2026.
- Corcept Therapeutics Allegations: From October 31, 2024, to December 30, 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, with a class action deadline of April 21, 2026.
- Navan, Inc. IPO Controversy: Navan is alleged to have failed to disclose a 39% increase in sales and marketing expenses during its IPO period in 2025, with a class action deadline of April 24, 2026.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Corcept Therapeutics, aiming to recover damages for investors who purchased securities between October 31, 2024, and December 30, 2025, reflecting strong investor concerns over potential fraudulent activities by the company.
- False Statements Allegations: The complaint alleges that executives made materially false statements regarding the efficacy of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA had raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Undisclosed Regulatory Risks: The lawsuit highlights that Corcept failed to disclose the significant risk that its relacorilant NDA might not be approved, creating a lack of transparency that exposes investors to substantial risks and negatively impacts the company's market reputation.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC emphasizes that they will represent investors on a contingency fee basis, meaning they will only charge fees if the lawsuit is successful, demonstrating their commitment to protecting investor rights and interests.
See More
Corcept Therapeutics Board Member Buys Over $3M in Shares
- Board Member Purchase: Leonard Baker Jr., a board member of Corcept Therapeutics, purchased 100,000 shares at an average price of approximately $33.14 each, totaling over $3 million, indicating strong confidence in the company's future prospects.
- Increased Ownership: This purchase raised Baker Jr.'s direct ownership in Corcept by about 2%, bringing his total to approximately 1.1 million shares, reflecting his recognition of the company's long-term value.
- Legal Challenge Context: The transaction occurred shortly after an unfavorable ruling in Corcept's patent dispute with Teva Pharmaceuticals, suggesting Baker Jr.'s confidence in the company's ability to navigate challenges despite legal setbacks.
- Future Revenue Guidance: Corcept outlines a revenue guidance of $900 million to $1 billion for 2026, as the anticipated approval of relacorilant in oncology approaches, sustaining market expectations for future growth.
See More
Insperity and Corcept Executives Increase Stock Holdings
- Insperity CEO Purchase: Insperity's CEO Paul J. Sarvadi bought 201,987 shares of NSP at $23.21 each on Thursday, totaling an investment of $4.69 million, indicating strong confidence in the company's future prospects.
- Positive Stock Performance: As of Friday, Insperity's stock rose approximately 10.8%, with Sarvadi's investment currently yielding about 9.4% profit, reflecting a favorable market response to the stock.
- Corcept Executive Acquisition: G. Leonard Baker Jr. purchased 100,000 shares of Corcept Therapeutics at $33.14 each on Tuesday, amounting to $3.31 million, marking his first purchase in the past year and signaling optimism about the company's outlook.
- Market Reaction: As of Friday, Corcept Therapeutics' stock increased by about 4.7%, with Baker Jr.'s investment also achieving approximately 9.4% profit, demonstrating market recognition of the stock.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to move for Lead Plaintiff in the ongoing securities class action is April 21, 2026, urging those who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: The lawsuit, Allegheny County v. Corcept, alleges that throughout the Class Period from 2024 to 2025, the company misled investors by failing to disclose FDA warnings regarding the efficacy of its lead drug candidate, relacorilant, leading to significant investor deception.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market pessimism about the company's future.
- Information Gap Issue: Reed Kathrein, a partner at Hagens Berman, highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, which may have led investors to misjudge the company's prospects, exacerbating their losses.
See More
